How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Narrower Quarterly Loss

Simply Wall St.12:36

NewAmsterdam Pharma reported third quarter 2026 sales of US$19.16 million and a net loss of US$17.39 million, with basic loss per share from continuing operations at US$0.14, compared with US$0.61 a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2683216523?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-11-13 12:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683216523","market":"sg","top_or_hot":-1,"title":"How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Narrower Quarterly Loss","media":"Simply Wall St.","content":"<div>\n<p>NewAmsterdam Pharma reported third quarter 2026 sales of US$19.16 million and a net loss of US$17.39 million, with basic loss per share from continuing operations at US$0.14, compared with US$0.61 a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/how-investors-are-reacting-to-newamsterdam-pharma-nams-narro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Narrower Quarterly Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To NewAmsterdam Pharma (NAMS) Narrower Quarterly Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-13 12:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/how-investors-are-reacting-to-newamsterdam-pharma-nams-narro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NewAmsterdam Pharma reported third quarter 2026 sales of US$19.16 million and a net loss of US$17.39 million, with basic loss per share from continuing operations at US$0.14, compared with US$0.61 a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/how-investors-are-reacting-to-newamsterdam-pharma-nams-narro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/how-investors-are-reacting-to-newamsterdam-pharma-nams-narro","article_id":"2683216523","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/how-investors-are-reacting-to-newamsterdam-pharma-nams-narro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683216523","pubTimestamp":1794544577,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AAl BentleyNovember 13, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","VOTE":"TCW Transform 500 ETF","RGLO":"Global Equity Active ETF","VGFPF":"Vanguard Funds PLC","NAMS":"NEWAMSTERDAM PHARMA CO NV","BK4139":"生物科技","BK4211":"区域性银行","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","GXDW":"Global X Dorsey Wright Thematic ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF"},"translate_title":"投资者对新阿姆斯特丹制药公司 (NAMS) 季度亏损收窄的反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":0.78,"FEBU":0.78,"ISBC":1.5,"VGFPF":0.78,"JOYT":0.78,"PMDE":0.78,"NAMS":1.5,"GXDW":0.78,"RGLO":0.78,"VOTE":0.78},"content_text":"NewAmsterdam Pharma reported third quarter 2026 sales of US$19.16 million and a net loss of US$17.39 million, with basic loss per share from continuing operations at US$0.14, compared with US$0.61 a year earlier. The sharp improvement in quarterly loss, even as the nine month net result stayed broadly similar year on year, highlights how NewAmsterdam Pharma’s cost base and revenue traction are starting to interact differently as obicetrapib advances. We will examine how NewAmsterdam Pharma’s investment narrative is shaped by this sharp quarterly sales increase and narrower reported loss.  Scan how NewAmsterdam Pharma’s earnings profile compares with other high research spend plays by reviewing the hand picked 20 high quality undiscovered gems in the sector. AdvertisementNewAmsterdam Pharma Investment Narrative Recap To own NewAmsterdam Pharma, you need to be comfortable with a late stage biotech that is still loss making and heavily tied to obicetrapib outcomes and commercialization. The sharp third quarter revenue step up to US$19.16 million, alongside a narrower quarterly loss of US$17.39 million, suggests operating leverage is starting to show through. The analyst consensus narrative on Simply Wall St frames the key catalyst as European Commission decisions on obicetrapib in 2026 and the PREVAIL interim analysis in early 2027. The latest earnings do not change those milestones. The main near term risk remains ongoing operating losses if obicetrapib revenue does not build as expected. The third quarter 2026 earnings release is the most relevant update. Sales reached US$19.16 million against US$0.35 million a year earlier, while the quarterly loss narrowed to US$17.39 million from US$72.01 million. For nine months, revenue was US$25.91 million and the loss was US$129.97 million, broadly in line with the prior period. For you as a shareholder or potential investor, this keeps the story anchored in execution. NewAmsterdam Pharma still needs regulatory decisions in Europe and trial readouts such as PREVAIL, REMBRANDT and RUBENS to support a path toward future profitability. Until then, the trade off between funding ongoing losses and potential future obicetrapib cash flows remains the central judgment call. NewAmsterdam Pharma's narrative projects US$528.0 million revenue and US$81.1 million earnings by 2029. This assumes revenue grows at a very large 320.1% yearly rate and requires earnings to move by about US$340.6 million from current earnings of a US$259.5 million loss. Uncover how NewAmsterdam Pharma's fair value indicates a 155% potential upside to its current price before the market closes that gap. NasdaqGM:NAMS 1-Year Stock Price Chart Exploring Other Perspectives One bearish angle on NewAmsterdam Pharma focuses on the risk that PREVAIL’s interim readout underwhelms, with external work suggesting only a 35% to 38% chance of hitting its MACE goal. Those same cautious analysts were only modeling about US$181.0 million of 2029 revenue and US$28.8 million of earnings before this earnings report, so their narrative is far more restrained than consensus. You can use this quarterly update as a chance to compare those more pessimistic assumptions with the new numbers and decide which storyline is closer to your own view. Explore 4 other NewAmsterdam Pharma fair value estimates, including one that suggests it could be worth just $50.56! Form Your Own Verdict Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision. See our latest analysis for NewAmsterdam Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.  Looking For More Ideas Beyond NewAmsterdam Pharma? If you want to stress test your thesis on NewAmsterdam Pharma, it can help to line it up against other potential opportunities using the Simply Wall St Screener. That way you are not relying on a single story, and can compare risk, balance sheet strength and income potential side by side.  If capital preservation comes first for you, check out a basket of 29 resilient stocks with low risk scores that may suit a more cautious approach. If you want quality at a price that still looks reasonable, scan a curated set of 32 high quality undervalued stocks with stronger fundamentals. If steady cash returns matter more than headline growth, review a focused group of 6 dividend fortresses that prioritize income.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if NewAmsterdam Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2683216523","isCrawlerRequest":true}